Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 1.13
GENE's Cash to Debt is ranked higher than
64% of the 258 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.82 vs. GENE: 1.13 )
GENE' s 10-Year Cash to Debt Range
Min: 1.13   Max: No Debt
Current: 1.13

Equity to Asset 0.27
GENE's Equity to Asset is ranked higher than
54% of the 241 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.64 vs. GENE: 0.27 )
GENE' s 10-Year Equity to Asset Range
Min: 0.27   Max: 0.88
Current: 0.27

0.27
0.88
F-Score: 2
Z-Score: -21.69
M-Score: 1.11
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -172.09
GENE's Operating margin (%) is ranked higher than
57% of the 255 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.61 vs. GENE: -172.09 )
GENE' s 10-Year Operating margin (%) Range
Min: -313.93   Max: 5.29
Current: -172.09

-313.93
5.29
Net-margin (%) -209.32
GENE's Net-margin (%) is ranked higher than
55% of the 255 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.20 vs. GENE: -209.32 )
GENE' s 10-Year Net-margin (%) Range
Min: -496.89   Max: 4.98
Current: -209.32

-496.89
4.98
ROE (%) -167.99
GENE's ROE (%) is ranked higher than
50% of the 233 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.21 vs. GENE: -167.99 )
GENE' s 10-Year ROE (%) Range
Min: -271.23   Max: 14.99
Current: -167.99

-271.23
14.99
ROA (%) -69.76
GENE's ROA (%) is ranked higher than
54% of the 260 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.22 vs. GENE: -69.76 )
GENE' s 10-Year ROA (%) Range
Min: -134.56   Max: 10.58
Current: -69.76

-134.56
10.58
ROC (Joel Greenblatt) (%) -425.58
GENE's ROC (Joel Greenblatt) (%) is ranked higher than
58% of the 259 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.02 vs. GENE: -425.58 )
GENE' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2051.16   Max: 66.03
Current: -425.58

-2051.16
66.03
Revenue Growth (3Y)(%) -41.50
GENE's Revenue Growth (3Y)(%) is ranked higher than
55% of the 190 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.50 vs. GENE: -41.50 )
GENE' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 58.7
Current: -41.5

0
58.7
» GENE's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

GENE Guru Trades in

GENE Guru Trades in

Q2 2014

GENE Guru Trades in Q2 2014

Jim Simons 18,000 sh (New)
» More
Q3 2014

GENE Guru Trades in Q3 2014

Jim Simons 108,800 sh (+504.44%)
» More
» Details

Insider Trades

Latest Guru Trades with GENE

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 2.80
GENE's P/S is ranked higher than
94% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.37 vs. GENE: 2.80 )
GENE' s 10-Year P/S Range
Min: 0.87   Max: 64
Current: 2.8

0.87
64
EV-to-EBIT -0.99
GENE's EV-to-EBIT is ranked higher than
73% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. GENE: -0.99 )
GENE' s 10-Year EV-to-EBIT Range
Min: -36.1   Max: 131.1
Current: -0.99

-36.1
131.1
Current Ratio 1.88
GENE's Current Ratio is ranked higher than
62% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.56 vs. GENE: 1.88 )
GENE' s 10-Year Current Ratio Range
Min: 1.08   Max: 5.22
Current: 1.88

1.08
5.22
Quick Ratio 1.79
GENE's Quick Ratio is ranked higher than
64% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.20 vs. GENE: 1.79 )
GENE' s 10-Year Quick Ratio Range
Min: 0.99   Max: 5.22
Current: 1.79

0.99
5.22
Days Inventory 28.29
GENE's Days Inventory is ranked higher than
88% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 133.28 vs. GENE: 28.29 )
GENE' s 10-Year Days Inventory Range
Min: 20.08   Max: 42.4
Current: 28.29

20.08
42.4
Days Sales Outstanding 134.10
GENE's Days Sales Outstanding is ranked higher than
61% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 75.04 vs. GENE: 134.10 )
GENE' s 10-Year Days Sales Outstanding Range
Min: 8.08   Max: 58.92
Current: 134.1

8.08
58.92

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.75
GENE's Price/Median PS Value is ranked higher than
99% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.38 vs. GENE: 0.75 )
GENE' s 10-Year Price/Median PS Value Range
Min: 0.32   Max: 15.25
Current: 0.75

0.32
15.25
Earnings Yield (Greenblatt) -107.40
GENE's Earnings Yield (Greenblatt) is ranked lower than
54% of the 255 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.10 vs. GENE: -107.40 )
GENE' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.8   Max: 1804.9
Current: -107.4

0.8
1804.9

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:GTG.Australia, GNTLF.USA, DU8.Germany,
Genetic Technologies Ltd is incorporated in Australia on January 05, 1987. The Company is a biotechnology company focused on expanding genetic testing business in the Asia-Pacific region and, with the addition of the BREVAGenTM breast cancer risk assessment test, in the U.S.A. and later in Europe. In addition, it is now pursuing commercial opportunities in other areas of activity: out-licensing non-coding patents; and supporting a late-stage research and development project in which it is already involved. The patents in the portfolio includes ntron Sequence Analysis; Genomic Mapping; Perlegen; BREVAGenTM; Laboratory Techniques; Ancestral Haplotypes; Athletic Performance;Nematode Project; and RareCellect Project.
» More Articles for GENE

Headlines

Articles On GuruFocus.com
Clinical Validation Study Supporting the Use of BREVAGenplus(R) in Breast Cancer Risk Assessment Dec 17 2014 
Genetic Technologies Launches BREVAGenplus(R) Breast Cancer Risk Assessment Test Oct 15 2014 
Genetic Technologies Announces Quarterly BREVAGen(TM) Results Oct 15 2014 

More From Other Websites
5:31 am Genetic Technologies announces up to 6 new breast centres to begin offering BREVAGenplus Jan 29 2015
Genetic Technologies Announces up to 6 New Breast Centres to Begin Offering BREVAGenplus(R) Jan 29 2015
Genetic Technologies Secures A$24 Million Standby Equity Placement Facility Jan 21 2015
Clinical Validation Study Supporting the Use of BREVAGenplus(R) in Breast Cancer Risk Assessment Dec 17 2014
PHENOGEN SCIENCES, INC. ANNOUNCES CLINICAL VALIDATION STUDY SUPPORTING THE USE OF BREVAGENPLUS(R) IN... Dec 16 2014
GENETIC TECHNOLOGIES LTD Financials Nov 04 2014
Genetic Technologies Announces Quarterly BREVAGen(TM) Results Oct 06 2014
Genetic Technologies Launches BREVAGenplus(R) Breast Cancer Risk Assessment Test Oct 01 2014
Genetic Technologies Announces Appointment of Independent Non-Executive Directors Sep 24 2014
Genetic Technologies Announces Divestment of Australian Based Heritage Business Sep 22 2014
Transformational Restructuring Plans to Support Molecular Diagnostics Focus and Finalisation of... Sep 15 2014
Genetic Technologies Announces Further Patent Success in USA Aug 26 2014
Why Genetic Technologies (GENE) Stock Is Spiking Today Jul 07 2014
Genetic Technologies provides BREVAGen revenue update Jul 07 2014
Genetic Technologies Provides BREVAGen(TM) Revenue Update for Quarter Ending June 30, 2014 Jul 07 2014
Appendix 3B Jun 27 2014
Genetic Technologies appoints Eutillio Buccilli as CFO May 29 2014
Genetic Technologies Announces Appointment of Chief Financial Officer May 28 2014
Genetic Technologies Announces Completion of Share Transaction With Dr. Mervyn Jacobson May 16 2014
Genetic Technologies Files Activities Report for the Quarter Ended March 31, 2014 Apr 30 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK